#None #Pomerantz LLP #Edgewise Therapeutics #EWTX

Investor Alert: Investigation into Edgewise Therapeutics, Inc.

Pomerantz LLP, a well-respected law firm specializing in corporate litigation, is currently investigating claims from investors of Edgewise Therapeutics, Inc. (NASDAQ: EWTX). This investigation aims to determine whether Edgewise and certain officers or directors have been involved in any fraudulent activities or breached their fiduciary duties, impacting shareholders adversely.

On June 26, 2025, Edgewise published a press release detailing the results of its clinical trials concerning sevasemten, its lead asset aimed at treating Becker and Duchenne muscular dystrophies. Although Edgewise presented the trial results as "positive," they also disclosed that the U.S. Food and Drug Administration (FDA) considered the data insufficient for expedited approval during a recent Type C meeting. Following this revelation, Edgewise's stock plummeted by $1.27, or 8.86%, closing at $14.33 per share on the same day.

This downward trend raises serious concerns among investors, prompting Pomerantz to investigate further. The firm advises all affected investors to reach out to Danielle Peyton at 646-581-9980, ext. 7980 or via email at [email protected]. Those interested in joining a potential class action should act promptly to protect their rights.

Pomerantz LLP has a long-standing tradition of advocating for victims of securities fraud and has successfully recovered substantial damages for numerous clients since its inception. Established by Abraham L. Pomerantz, considered one of the pioneers in class action law, the firm has cultivated a reputation for its diligence and effectiveness in the realm of corporate misconduct and shareholder rights.

The firm's investigation is part of its ongoing commitment to ensuring accountability in the corporate world, especially in instances where investors face potential financial losses due to deceptive practices. If you are an investor who has experienced a loss due to Edgewise's actions or misrepresentations, it is crucial to explore your legal options.

In summary, the implications of this investigation by Pomerantz LLP could have significant ramifications for Edgewise Therapeutics and its shareholders. The firm continues to encourage investors to come forward and share their experiences. The integrity of the financial markets relies heavily on transparency, and actions such as those being examined by Pomerantz serve to uphold these principles.

For further information about this investigation and to learn more about your rights as a shareholder, visit Pomerantz Law Firm's website. Stay informed about this developing story as more details emerge regarding Edgewise Therapeutics and the outcome of the legal inquiries.

• ---

Contact Information
Danielle Peyton
Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980 ext. 7980